Table 4.

Moderate or More Physical Activity (hours/week) and Sex Hormone Levels in EPAT Participants (n=194)

	Beta*	95% Confidence Interval	P-value (Linear trend)	P-value (Tertile Trend)
Placebo participants (n=104)
Estradiol (pg/ml)	−0.002	−0.01, 0.01	0.54	0.99
Estrone (pg/ml)	−0.002	−0.01, 0.01	0.60	0.61
Bioavailable Estradiol (pg/ml)	−0.10	−0.22, 0.02	0.09	0.09
Free Estradiol (pg/ml)	−0.004	−0.01, 0.001	0.09	0.09
Testosterone (ng/dl)	−0.31	−0.54, −0.09	0.006	0.004
DHEA (ng/ml)	0.03	−0.002, 0.06	0.07	0.11
Androstenedione (pg/ml)	−1.91	−6.75, 2.92	0.44	0.88
Bioavailable testosterone (ng/ml)	−0.21	−0.31, −0.12	<0.001	<0.001
Free Testosterone (pg/ml)	−0.10	−0.14, −0.05	<0.001	<0.001
SHBG (nmol/l)	0.82	0.41, 1.23	<0.001	<0.001
Estradiol Participants (n=90)
Estradiol (pg/ml)	−1.38	−2.15, −0.62	<0.001	0.03
Estrone (pg/ml)	−4.02	−8.85, 0.80	0.10	0.88
Bioavailable Estradiol (pg/ml)	−0.80	−1.27, −033	<0.001	0.05
Free Estradiol (pg/ml)	−0.03	−0.05, −0.01	<0.001	0.05
Testosterone (ng/dl)	−0.04	−0.37, 0.29	0.81	0.18
DHEA (ng/ml)	0.01	−0.01, 0.04	0.33	0.001
Androstenedione (pg/ml)	1.50	−4.26, 7.23	0.61	0.005
Bioavailable testosterone (ng/ml)	−0.006	−0.11, 0.10	0.92	0.67
Free Testosterone (pg/ml)	−0.002	−0.05, 0.05	0.92	0.66
SHBG (nmol/l)	0.10	0.58, 0.77	0.80	0.33

^*Regression coefficient = mean difference in hormone/SHBG level per hour of moderate or more activity, adjusted for age, race, body mass index, type of menopause

EPAT: Estrogen in the Prevention of Atherosclerosis Trial; MET; Metabolic equivalents of energy expenditure;

SHBG: Sex hormone-binding globulin; DHEA: Dehydroepiandrosterone